VEGFR3 blockade reduces metastatic spread and lymphangiogenesis in a number of tumor models, as the VEGFC : VEGFR3 signaling pathway is one of the quintessential drivers of LEC proliferation and lymphatic expansion (11). Here, VEGFC is linked to neoplasm.